Motivational Interview in Adolescents With Poorly Controlled Type 1 Diabetes
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02637154 |
Recruitment Status : Unknown
Verified August 2018 by Mari Pulkkinen, Helsinki University Central Hospital.
Recruitment status was: Active, not recruiting
First Posted : December 22, 2015
Last Update Posted : August 3, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study investigates the effect of motivational interviewing and intensive education on HbA1c values and glucose variability in poorly controlled adolescent T1D patients.
In the present study motivational interviewing (MI) will be integrated to clinicians' daily practice, as a part of normal clinical visit. In this randomized, controlled trial hypothesis is, that applying motivational interviewing during regular clinical visits results in better acceptance and subsequently enhanced metabolic control in adolescents with poorly controlled type 1 diabetes.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetes Mellitus, Type 1 | Behavioral: Motivational Interviewing Behavioral: Standard Education | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Supportive Care |
Official Title: | The Effect of Motivational Interview and Intensive Education on HbA1C Values and Glucose Variability in Adolescents With Poorly Controlled Type 1 Diabetes |
Actual Study Start Date : | October 15, 2015 |
Estimated Primary Completion Date : | September 2018 |
Estimated Study Completion Date : | December 2018 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Motivational Interviewing
With 30 patients Motivational Interviewing method will be used during each visit
|
Behavioral: Motivational Interviewing
Motivational Interviewing method |
Active Comparator: Standard Education
With 30 patients Standard Education material will be used during each visit
|
Behavioral: Standard Education
Standard Education material will be used |
- Change in HbA1C values (mmol/mol) [ Time Frame: 12 months ]HbA1c levels (mmol/mol) are measured in every visit (AfinionTM).
- Change in glycaemic variability [ Time Frame: 12 months ]Six days blinded continuous glucose monitoring (CGM) (iPro, Medtronic) will be performed at baseline and during the follow-up. Blinded CGM curves (0 and 12mo) will be analyzed to study effect on glycemic variability. Standard deviation (SD) of blood glucose values and mean amplitude of glycemic excursions (MAGE) will be used as parameters to define glycemic variability.
- Influence of changes in markers of vascular health (IMT) [ Time Frame: 12 months ]The association between glycemic control and vascular wall morphology is assessed by imaging of the carotid, femoral, brachial and radial artery intima media thickness (IMT as millimeters - mm:s) with ultrasound. Results will be compared to previously established measurements from healthy children. Vascular assessment will be performed at baseline and at study completion.
- Influence of changes in markers of vascular health (PWV) [ Time Frame: 12 months ]The association between glycemic control and central and peripheral arterial thickness is assessed with pulse wave velocity (PWV - as meters / second - m/s) using applanation tonometry. Results will be compared to previously established measurements from healthy children. Vascular assessments will be performed at baseline and at study completion.
- Influence of changes in bone mineral density (BMD) [ Time Frame: 12 months ]Dual- energy x-absorptiometry (DXA) is performed at baseline and at 12 months for analyses of BMD (total body less head, lumbar spine) and body composition, using the Hologic Discovery device (indicated as SD of Z-score).
- Influence of changes in quality of life [ Time Frame: 12 months ]Health related quality of life (QoL) in study participants will be evaluated at baseline, and at completion of the study with the KINDL-R questionnaires
- Influence of changes in markers of inflammation (IL-6 - pg/ml) [ Time Frame: 12 months ]Fasting venous blood samples are obtained at baseline and at 12 months for later analysis of serum inflammatory marker serum IL-6.
- Influence of changes in markers of inflammation (high-sensitive-c-reactive-protein CRP - mg/l). [ Time Frame: 12 months ]Fasting venous blood samples are obtained at baseline and at 12 months for later analysis of serum inflammatory marker hs-CRP.
- Influence of changes in insulin-like-growth-factor IGF-I levels [ Time Frame: 12 months ]Fasting venous blood samples are obtained at baseline and at 12 months for later analysis of serum insulin-like-growth-factor IGF-I (ng/ml) levels.
- Influence of changes in markers of bone turnover (serum aminoterminal propeptide of type I collagen (PINP - ng/ml)). [ Time Frame: 12 months ]Fasting venous blood samples are obtained at baseline and at 12 months for later analysis of markers of bone turnover (PINP - ng/ml).
- Influence of changes in vitamin D status (25-hydroxy-D) ng/ml [ Time Frame: 12 months ]Fasting venous blood samples are obtained at baseline and at 12 months for analysis of changes in vitamin D status.
- Influence of changes in marker of bone turnover: osteocalcin (ng/ml) [ Time Frame: 12 months ]Fasting venous blood samples are obtained at baseline and at 12 months for analysis of changes in bone turnover marker osteocalcin.
- Influence of changes in marker of bone turnover: aminoterminal telopeptide of type I collagen (INTP - ng/ml) [ Time Frame: 12 months ]Fasting venous blood samples are obtained at baseline and at 12 months for analysis of changes in bone turnover marker INTP.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 16 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- the diagnosis of type 1 diabetes with at least 2 years duration and HbA1c > 75 mmol/mol on two consecutive visits, age 12-15.9 years and pubertal (Tanner) stage 2 or more at inclusion
Exclusion Criteria:
- celiac disease with poor control; diagnosis of psychiatric disease; and other chronic disease requiring per oral glucocorticoid treatment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02637154
Finland | |
Helsinki University Central Hospital, Pediatric Diabetes Unit Espoo | |
Espoo, Finland, 00029 | |
Helsinki University Central Hospital, Pediatric Endocrinology Unit | |
Helsinki, Finland, 00029 | |
Oulu University Hospital, Pediatric Endocrinology Unit | |
Oulu, Finland |
Principal Investigator: | Mari Pulkkinen, MD PhD | Specialist in Pediatric Endocrinology |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Mari Pulkkinen, MD, PhD, Helsinki University Central Hospital |
ClinicalTrials.gov Identifier: | NCT02637154 |
Other Study ID Numbers: |
MoHa |
First Posted: | December 22, 2015 Key Record Dates |
Last Update Posted: | August 3, 2018 |
Last Verified: | August 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Adolescent Type 1 diabetes Metabolic control Motivational interviewing |
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Autoimmune Diseases Immune System Diseases |